Mode of Action of the Amaryllidaceae Alkaloid Lycorine-Promising Anticancer Agent
石蒜科生物碱石蒜碱的作用方式有前途的抗癌剂
基本信息
- 批准号:8763979
- 负责人:
- 金额:$ 47.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-15 至 2017-06-30
- 项目状态:已结题
- 来源:
- 关键词:ActinsAlkaloidsAlkynesAmaryllidaceae AlkaloidsAntineoplastic AgentsApoptosisApoptoticAvidinBackBindingBinding ProteinsBiologicalBiological AssayBiological FactorsBiologyBiotinBrainBrain NeoplasmsCancer PatientCancer cell lineCell LineChemicalsComputersCytoskeletonDataDevelopmentDoseEvaluationExhibitsFoundationsFutureGlioblastomaGliomaGoalsInduction of ApoptosisInvestigationKnowledgeMalignant NeoplasmsMelanoma CellModelingMusNeoplasm MetastasisNon-Small-Cell Lung CarcinomaNormal CellOutcomePharmaceutical PreparationsPhotoaffinity LabelsPreparationProbabilityPropertyProteinsRelative (related person)ResearchResistanceSiteSolidStimulusStructureTherapeuticTimeValidationWorkanalogbasecancer cellcancer therapycancer typedesigndrug discoveryexperienceimprovedin vivoinnovationmelanomamigrationmouse modelneoplastic cellnovelnovel strategiesnovel therapeuticsoutcome forecastpharmacophorepublic health relevancetreatment strategytumor
项目摘要
DESCRIPTION (provided by applicant): The ultimate goal of this project is the development of a novel therapeutic strategy for the treatment of cancer capitalizing on the unique antiproliferative effects of the alkaloid lycorine on apoptosis resistant cancers. Although a large
majority of current cancer drugs exhibit their effects through the induction of apoptosis in tumor cells, many types of cancer, such as glioma, melanoma, NSCLC, among others, are resistant to proapoptotic stimuli and are typically associated with dismal prognoses. Therefore, new chemotypes that display antiproliferative effects against such apoptosis-resistant cancers and/or inhibit tumor metastatic spread are urgently needed. In preliminary work, the PI's collaborative chemical biology/drug discovery team has shown that the alkaloid lycorine modifies actin cytoskeleton organization in cancer cells, and impairs both their proliferation and migration. Lycorine exerts these effects with both apoptotic-resistant and susceptible cell lines, sensitizes cancer cells to proapoptotic agents, and displays 15 times greater potency toward cancer versus normal cells. Furthermore, lycorine showed significant therapeutic benefit in vivo in the B16F10 mouse melanoma model, consisting of orthotopically brain-grafted melanoma cells. These preliminary results form a compelling case for a thorough understanding of lycorine's mode of action in cancer cells and utilization of this knowledge for the development of novel strategies to treat cancers with dismal prognoses. The proposed work involves the preparation of lycorine- alkyne probes, which will be evaluated against a panel of apoptosis-resistant cancer cells with the goal of identifying derivatives retaining the antiproliferative potency and mode of action of lycorine. Suitable alkyne probes will then be used in protein pull-down assays, aimed at target protein identification. Several back-up target identification and target validation strategies are also proposed to confirm this innovative chemotherapeutic approach.
描述(由申请人提供):该项目的最终目标是开发一种新型的治疗策略,用于治疗癌症,以利用生物碱番茄糖对抗细胞凋亡癌的独特抗增殖作用。虽然很大
当前大多数癌症药物通过诱导肿瘤细胞的凋亡而表现出其作用,肿瘤细胞中的许多类型的癌症,例如神经胶质瘤,黑色素瘤,NSCLC等,对促凋亡刺激具有抵抗力,通常与沮丧的预测有关。因此,迫切需要对这种抗凋亡癌和/或抑制肿瘤转移性扩散的新的化学型,这些化学型表现出抗增殖作用。在初步工作中,PI的合作化学生物学/药物发现团队表明,生物碱氨基氨酸修饰癌细胞中的肌动蛋白细胞骨架组织,并损害其增殖和迁移。番茄与凋亡耐药性和易感细胞系一起发挥这些作用,使癌细胞对促凋亡剂敏感,并显示出对癌症与正常细胞相对于正常细胞的效力的15倍。此外,在B16F10小鼠黑色素瘤模型中,氨核在体内显示出显着的治疗益处,由原位脑植血的黑色素瘤细胞组成。这些初步结果构成了一个令人信服的案例,可以透彻地了解番茄碱在癌细胞中的作用方式,并利用这种知识来开发新型策略,以惨淡的预后治疗癌症。提出的工作涉及番茄碱探针的制备,该探针将针对一组耐凋亡的癌细胞进行评估,其目的是鉴定衍生物保持抗增殖效力和番茄的作用方式。然后,合适的炔烃探针将用于针对靶蛋白鉴定的蛋白质下拉测定法。还提出了几种备用目标识别和目标验证策略,以确认这种创新的化学治疗方法。
项目成果
期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Novel Topologically Complex Scaffold Derived from Alkaloid Haemanthamine.
- DOI:10.3390/molecules23020255
- 发表时间:2018-01-28
- 期刊:
- 影响因子:0
- 作者:Govindaraju K;Masi M;Colin M;Mathieu V;Evidente A;Hudnall TW;Kornienko A
- 通讯作者:Kornienko A
Covalent modification of biological targets with natural products through Paal-Knorr pyrrole formation.
- DOI:10.1039/c7np00024c
- 发表时间:2017-08-30
- 期刊:
- 影响因子:11.9
- 作者:Kornienko A;La Clair JJ
- 通讯作者:La Clair JJ
Higginsianins A and B, Two Diterpenoid α-Pyrones Produced by Colletotrichum higginsianum, with in Vitro Cytostatic Activity.
- DOI:10.1021/acs.jnatprod.5b00779
- 发表时间:2016-01-22
- 期刊:
- 影响因子:5.1
- 作者:Cimmino A;Mathieu V;Masi M;Baroncelli R;Boari A;Pescitelli G;Ferderin M;Lisy R;Evidente M;Tuzi A;Zonno MC;Kornienko A;Kiss R;Evidente A
- 通讯作者:Evidente A
Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.
- DOI:10.1002/med.21423
- 发表时间:2017-07
- 期刊:
- 影响因子:13.3
- 作者:Ciavatta ML;Lefranc F;Carbone M;Mollo E;Gavagnin M;Betancourt T;Dasari R;Kornienko A;Kiss R
- 通讯作者:Kiss R
Sesterterpenoids with Anticancer Activity.
- DOI:10.2174/0929867322666150821101047
- 发表时间:2015
- 期刊:
- 影响因子:4.1
- 作者:Evidente A;Kornienko A;Lefranc F;Cimmino A;Dasari R;Evidente M;Mathieu V;Kiss R
- 通讯作者:Kiss R
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALEXANDER KORNIENKO其他文献
ALEXANDER KORNIENKO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALEXANDER KORNIENKO', 18)}}的其他基金
Tandem Discovery of Drug Leads and Targets via Paal-Knorr reaction
通过 Paal-Knorr 反应串联发现先导药物和靶标
- 批准号:
10004127 - 财政年份:2019
- 资助金额:
$ 47.55万 - 项目类别:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
胰酶抑制素细胞毒性药效团的阐明
- 批准号:
7960231 - 财政年份:2009
- 资助金额:
$ 47.55万 - 项目类别:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
胰酶抑制素细胞毒性药效团的阐明
- 批准号:
7720456 - 财政年份:2008
- 资助金额:
$ 47.55万 - 项目类别:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
胰酶抑制素细胞毒性药效团的阐明
- 批准号:
7610367 - 财政年份:2007
- 资助金额:
$ 47.55万 - 项目类别:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
胰酶抑制素细胞毒性药效团的阐明
- 批准号:
7381756 - 财政年份:2006
- 资助金额:
$ 47.55万 - 项目类别:
ELUCIDATION OF THE PANCRATISTATIN CYTOTOXIC PHARMACOPHORE
胰酶抑制素细胞毒性药效团的阐明
- 批准号:
7170976 - 财政年份:2005
- 资助金额:
$ 47.55万 - 项目类别:
Enantiodivergent Synthesis of (+) and (-) Pancratistatin
( ) 和 (-) Pancratistatin 的对映异构合成
- 批准号:
6593475 - 财政年份:2003
- 资助金额:
$ 47.55万 - 项目类别:
Enantiodivergent Synthesis of (+) and (-) Pancratistatin
( ) 和 (-) Pancratistatin 的对映异构合成
- 批准号:
6896624 - 财政年份:2003
- 资助金额:
$ 47.55万 - 项目类别:
相似国自然基金
叶底珠生物碱suffranidine A的全合成研究
- 批准号:22371239
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
从AMPK调控线粒体裂变和融合研究金钗石斛总生物碱抗非酒精性脂肪肝病的分子机制
- 批准号:82360808
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
基于S1P-S1PR1-RANKL信号轴调控成骨-破骨细胞耦合平衡探究黄连生物碱代谢物治疗糖尿病型骨质疏松症的作用机制
- 批准号:82305270
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
C3-烷基型吡咯并吲哚生物碱的高效多样性生物合成研究
- 批准号:22307069
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
大叶糖胶树中作用于单胺氧化酶B和转录因子EB的双靶点抗PD生物碱的发现与机制研究
- 批准号:82304330
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Harnessing Atropisomerism in beta-Carbolines for the Discovery of New Reactions and Small Molecule Probes
利用 β-咔啉中的阻转异构现象来发现新反应和小分子探针
- 批准号:
10730343 - 财政年份:2023
- 资助金额:
$ 47.55万 - 项目类别:
Aza-Heck/C-C cleavage/cross coupling cascades of pinene derivatives for the synthesis of zoanthamine alkaloids
蒎烯衍生物的 Aza-Heck/C-C 裂解/交叉偶联级联用于合成佐安胺生物碱
- 批准号:
10328890 - 财政年份:2021
- 资助金额:
$ 47.55万 - 项目类别:
Aza-Heck/C-C cleavage/cross coupling cascades of pinene derivatives for the synthesis of zoanthamine alkaloids
蒎烯衍生物的 Aza-Heck/C-C 裂解/交叉偶联级联用于合成佐安胺生物碱
- 批准号:
10540775 - 财政年份:2021
- 资助金额:
$ 47.55万 - 项目类别:
Method and Strategy Development for the Synthesis of Physiologically Important Natural Products
合成具有生理重要性的天然产物的方法和策略开发
- 批准号:
10132361 - 财政年份:2020
- 资助金额:
$ 47.55万 - 项目类别: